Differin

Differin is a dermatology brand best known for adapalene, a topical retinoid used to treat acne vulgaris. The brand originated as a prescription acne treatment and later became one of the most recognizable consumer acne brands in the United States after adapalene 0.1% gel was approved for over-the-counter sale. Its principal product, Differin Gel 0.1%, is applied once daily and is intended to help clear existing acne and reduce the formation of new lesions. Adapalene works by normalizing the growth and shedding of skin cells within pores and by reducing processes associated with acne inflammation. As with other topical retinoids, the product can cause dryness, redness, scaling, stinging, or irritation, particularly during the initial weeks of use. The consumer brand therefore emphasizes gradual introduction, appropriate moisturization, sunscreen use, and following the product label or professional medical advice. Differin is not positioned as a cosmetic skin-care line alone; its central identity is as an over-the-counter acne medicine supported by a prescription dermatology heritage. The brand has expanded beyond its flagship gel with cleansers, moisturizers, and other acne-care products intended to complement treatment and address irritation or excess oil. Its retail presence includes pharmacies, mass retailers, supermarkets, and e-commerce channels. Galderma, a dermatology company with roots in prescription and professional skin health, markets the brand in the United States and selected international markets. Differin's major commercial turning point came in 2016, when the U.S. Food and Drug Administration approved adapalene 0.1% gel for nonprescription use in people aged 12 and older. This made a formerly prescription-only topical retinoid available directly to consumers and helped establish the brand as an accessible first-line option for acne self-care. The product remains subject to drug-label directions and is not appropriate for every user; persistent, severe, scarring, or treatment-resistant acne may require professional evaluation. Differin's competitive set includes benzoyl peroxide products, salicylic-acid acne treatments, other topical retinoids, and prescription acne medicines. The brand's distinctive proposition is the retail availability of a clinically established retinoid rather than a purely cosmetic spot-treatment approach.

Differin's history is tied to the development and commercialization of adapalene, a third-generation topical retinoid designed for acne treatment. Unlike older topical retinoids, adapalene was developed with the goal of providing effective comedolytic and anti-inflammatory activity with a useful tolerability profile. Differin became the principal brand associated with adapalene in dermatology markets and was initially supplied under prescription. Its early role was therefore primarily clinical: dermatologists used it as a topical treatment for acne vulgaris, either alone or alongside antimicrobial or other acne therapies. The brand's prescription heritage helped distinguish it from cosmetic products and from over-the-counter preparations based mainly on benzoyl peroxide or salicylic acid. A major change occurred in the United States in 2016. The FDA approved Differin Gel 0.1%, containing adapalene, for over-the-counter use in people aged 12 and older. This was significant because it made the first topical retinoid of its kind available without a prescription in the U.S. The approval was based on the established use and safety information for adapalene, together with the regulatory review supporting the switch from prescription to nonprescription status. The U.S. launch followed in 2017, moving Differin from a primarily physician-mediated product into a widely distributed pharmacy and mass-retail brand. The OTC positioning did not eliminate the medicine's clinical character. Label directions continued to emphasize once-daily application, use over the acne-prone area rather than only individual spots, and the possibility of an initial adjustment period involving dryness or irritation. Consumer communication also encouraged moisturization and sun protection and warned users to seek medical advice when acne is severe or does not improve. After the OTC launch, the brand broadened its shelf presence with complementary cleansers and moisturizers. These products supported a complete acne-care routine and helped the brand address common concerns among new retinoid users, including oiliness, dryness, and sensitivity. Differin's core product nevertheless remained adapalene gel rather than a broad beauty portfolio. In 2019, Galderma became an independent dermatology company after its separation from Nestlé's skin-health business. Differin continued within Galderma's dermatology-focused brand portfolio. Galderma later became a publicly listed company in Switzerland, while Differin remained a consumer-facing brand rather than a separately listed corporation. The brand's development illustrates the movement of selected prescription dermatology medicines into consumer self-care. Its commercial proposition combines a familiar pharmaceutical active ingredient, a clear acne indication, and the convenience of retail purchase. At the same time, the brand operates within the constraints of a regulated medicine category: claims must correspond to the approved labeling, instructions must address safe use, and marketing must avoid presenting acne treatment as merely cosmetic. Differin competes with benzoyl peroxide and salicylic-acid products in mass retail, with other topical retinoids in dermatology, and with prescription combinations for more complex acne. Its continuing relevance rests on adapalene's role as an established topical retinoid and on the accessibility created by OTC distribution.

• 2024

  Galderma lists on the SIX Swiss Exchange

  [5]Galderma announces pricing of initial public offeringgalderma.com

  Galderma Group AG became a publicly listed company in Switzerland; Differin remained a brand within the group.

• 2019

  Galderma becomes independent

  [4]Galderma completes acquisition of Nestlé Skin Healthgalderma.com

  Galderma completed its separation from Nestlé's skin-health business and continued operating Differin within its dermatology portfolio.

• 2017

  U.S. retail launch

  [2]Differin official consumer websitedifferin.com

  Differin Gel 0.1% became available through U.S. retail channels without a prescription.

• 2016

  OTC switch approved

  [1]FDA approves first over-the-counter topical acne treatmentfda.gov

  The FDA approved Differin Gel 0.1% for over-the-counter sale to consumers aged 12 and older.

• 1996

  Adapalene receives U.S. prescription approval

  [3]FDA Drugs@FDA databaseaccessdata.fda.gov

  The FDA approved adapalene for prescription treatment of acne, establishing the regulatory foundation for the Differin brand in the United States.

An accessible, dermatologist-oriented acne-treatment brand built around adapalene, combining prescription-drug heritage with over-the-counter retail availability.

• Topical acne medicine · 2017

  Differin Gel 0.1% Adapalene Acne Treatment

  The flagship Differin product is a once-daily topical gel containing 0.1% adapalene. It is indicated for the treatment of acne in consumers aged 12 and older under the U.S. OTC label. Adapalene helps normalize abnormal skin-cell shedding within pores and has anti-inflammatory activity. The gel is intended for consistent application to the acne-prone area rather than occasional spot use. Dryness, redness, scaling, and irritation may occur, especially when treatment begins, so the brand's routine guidance commonly includes gentle cleansing, moisturization, and daytime sun protection.

• Acne cleanser

  Differin Daily Deep Cleanser

  A complementary cleanser sold within the Differin acne-care range. Its role is to remove oil, dirt, and residue from acne-prone skin while fitting into a routine that may also include adapalene. The cleanser is not the brand's primary retinoid medicine; it supports preparation and ongoing care around the central acne-treatment product.

• Moisturizer and sunscreen

  Differin Oil Absorbing Moisturizer with SPF

  A supporting skin-care product designed for acne-prone or oily skin and intended to provide moisturization alongside daytime sun protection. Products of this type complement adapalene routines because topical retinoids can produce dryness or sensitivity during treatment. It is a companion product rather than the active acne medicine represented by Differin Gel.

• 2017Differin OTC launch education

  United States

  The U.S. OTC launch used consumer education to explain adapalene, daily use, the expected adjustment period, and the importance of a supportive skin-care routine.

  Outcome. The campaign helped reposition Differin from a prescription dermatology product as an accessible retail acne medicine.

  Source

• 2019

  Transfer of Differin into independent GaldermaM&A

  Background

  Nestlé reorganized its skin-health business, separating Galderma from the Nestlé group.

  Action taken

  Galderma became an independent dermatology company and continued to manage Differin as part of its portfolio.

  Aftermath

  Differin remained aligned with a dermatology-focused company rather than a general consumer-goods parent.

  Source

• 2017

  Launch Differin Gel as a U.S. OTC acne medicineProduct launch

  Background

  The FDA's switch approval allowed the brand to move beyond prescription channels.

  Action taken

  Differin Gel 0.1% was introduced through pharmacies, mass retailers, and other consumer channels.

  Aftermath

  Differin became a prominent retail adapalene brand and expanded its consumer-facing acne-care ecosystem.

  Source

• 2016

  Switch adapalene 0.1% from prescription to OTC statusStrategy

  Background

  Adapalene had an established prescription history, while acne remained a large consumer self-care category. Regulatory approval created an opportunity to make the medicine available directly to consumers.

  Action taken

  The FDA approved Differin Gel 0.1% for nonprescription use in people aged 12 and older.

  Aftermath

  The product entered U.S. retail distribution in 2017 and became the brand's defining commercial proposition.

  Source

1. 1FDA approves first over-the-counter topical acne treatmentfda.gov
2. 2Differin official consumer websitedifferin.com
3. 3FDA Drugs@FDA databaseaccessdata.fda.gov
4. 4Galderma completes acquisition of Nestlé Skin Healthgalderma.com
5. 5Galderma announces pricing of initial public offeringgalderma.com